Tepotinib Efficacy in a Patient with Non‐Small Cell Lung Cancer with Brain Metastasis Harboring an HLA‐DRB1‐MET Gene Fusion. (8th September 2020)

• Record Type: Journal Article
• Authors: Blanc‐Durand, Félix; Alameddine, Raafat; Iafrate, Anthony J.; Tran‐Thanh, Danh; Lo, Ying‐Chun; Blais, Normand; Routy, Bertrand; Tehfé, Mustapha; Leduc, Charles; Romeo, Phillipe; Stephenson, Phillipe; Florescu, Marie
• Is Part Of: Oncologist. Volume 25:Number 11(2020)
• Page Start: 916
• Page End: 920
• Publication Date: 2020-09-08
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2020-0502
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: : Alterations in c‐MET, a tyrosine kinase receptor encoded by the MET gene, have been reported in approximately 3% of non‐small cell lung cancer (NSCLC) cases and carry important treatment implications. The best studied genetic alterations are exon 14 skipping and gene amplification; however, gene rearrangement has also been described, and multiple fusion partners have been reported. Recently, in MET ex14‐mutated NSCLC, multitarget tyrosine kinase inhibitors (TKIs), such as crizotinib and cabozantinib, as well as MET‐selective TKIs, such as tepotinib and capmatinib, have demonstrated durable responses. In this study, we present the case of a 41‐year‐old woman with advanced NSCLC harboring an HLA‐DRB1‐MET gene fusion. The patient was offered successively two different MET multikinase inhibitors, crizotinib and cabozantinib, and the selective inhibitor tepotinib. Each time, including under tepotinib, the patient experienced rapid and complete responses associated with a tremendous improvement in her physical function. Key Points : To our knowledge, this is the first report of a patient with non‐small cell lung cancer harboring an HLA‐DRB1‐MET gene fusion demonstrating a clinical response to multiple MET inhibitors, including tepotinib. This finding illustrates the efficacy and rationale to targeting MET regardless of fusion partner and gives insight to pooling of patients with different MET fusion products in trials assessing safety and efficacy of novel molecules. Abstract : This article provides a promising report of tepotinib efficacy in a patient with non‐small cell lung cancer harboring an HLA‐DRB1‐MET gene fusion.